

T7-362-T100

Monoclonal Antibody to CD95 / Fas PE-Cy[™]7 conjugated (100 tests)

Clone: LT95

Isotype: Mouse IgG1

Specificity: The antibody LT95 reacts with CD95 (Fas/APO-1), a 46 kDa single chain type I

glycoprotein of the tumour necrosis factor/nerve growth factor (TNF/NGF) receptor

superfamily, expressed on a variety of normal and neoplastic cells.

It seems that the antibody LT95 does not induce Fas mediated apoptosis, although it cross-blocks anti-Fas DX2 antibody that recognizes a functional epitope of Fas

molecule.

Regulatory Status: RUO

Immunogen: HUT-78 human T cell lymphoma cell line

Species Reactivity: Human

Preparation: The purified antibody is conjugated with tandem dye PE-Cy™7 under optimum

conditions. The conjugate is purified by size-exclusion chromatography and

adjusted for direct use. No reconstitution is necessary.

Storage Buffer: The reagent is provided in stabilizing phosphate buffered saline (PBS) solution

containing 15mM sodium azide.

Storage / Stability: Store in the dark at 2-8°C. Do not freeze. Avoid prolonged exposure to light. Do not

use after expiration date stamped on vial label.

Usage: The reagent is designed for Flow Cytometry analysis of human blood cells using 4

μl reagent / 100 μl of whole blood or 10° cells in a suspension.

The content of a vial (0.4 ml) is sufficient for 100 tests.

Expiration: See vial label

Lot Number: See vial label

Background: CD95 (Fas, APO-1), a 46 kDa transmembrane glycoprotein, is a cell death

receptor of the TNFR superfamily. Stimulation of CD95 results in aggregation of its intracellular death domains, formation of the death-inducing signaling complex (DISC) and activation of caspases. In type I cells caspase 3 is activated by high amounts of caspase 8 generated at the DISC, in type II cells low concentration of caspase 8 activates pathway leading to the release of cytochrome c from mitochondria and activation of caspase 3 by cytochom c. Besides its roles in induction of apoptosis, Fas also triggers pro-inflammatory cytokine responses.



PRODUCT DATA SHEET

References:

*Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ, Debatin KM, Krammer PH, Peter ME: Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 1998 Mar 16;17(6):1675-87.

*Park DR, Thomsen AR, Frevert CW, Pham U, Skerrett SJ, Kiener PA, Liles WC: Fas (CD95) induces proinflammatory cytokine responses by human monocytes and monocyte-derived macrophages. J Immunol. 2003 Jun 15;170(12):6209-16. *Guo Z, Zhang M, Tang H, Cao X: Fas signal links innate and adaptive immunity by promoting dendritic-cell secretion of CC and CXC chemokines. Blood. 2005 Sep 15;106(6):2033-41.

*Brumatti G, Yon M, Castro FA, Bueno-da-Silva AE, Jacysyn JF, Brunner T, Amarante-Mendes GP: Conversion of CD95 (Fas) Type II into Type I signaling by sub-lethal doses of cycloheximide. Exp Cell Res. 2008 Feb 1;314(3):554-63. *Drosopoulos KG, Roberts ML, Cermak L, Sasazuki T, Shirasawa S, Andera L, Pintzas A.: Transformation by oncogenic RAS sensitizes human colon cells to TRAIL-induced apoptosis by up-regulating death receptor 4 and death receptor 5 through a MEK-dependent pathway. J Biol Chem. 2005 Jun 17;280(24):22856-67.

Epub 2005 Mar 8.

Unless indicated otherwise, all products are For Research Use Only and not for diagnostic or therapeutic use. Not for resale or transfer either as a stand-alone product or as a component of another product without written consent of EXBIO. EXBIO will not be held responsible for patent infringement or other violations that may occur with the use of our products. All orders are accepted subject to EXBIO's term and conditions which are available at www.exbio.cz.

Cy™ and CyDye™ are registered trademarks of GE Healthcare.